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Abstract
Background: Cell fusion is a fast and highly efficient technique for cells to acquire new properties. The fusion of
somatic cells with stem cells can reprogram somatic cells to a pluripotent state. Our research on the fusion of stem
cells and cancer cells demonstrates that the fused cells can exhibit stemness and cancer cell-like characteristics.
Thus, tumor-initiating cell-like cells are generated.
Methods: We employed laser-induced single-cell fusion technique to fuse the hepatocellular carcinoma cells and
human embryonic stem cells (hESC). Real-time RT-PCR, flow cytometry and in vivo tumorigenicity assay were adopted
to identify the gene expression difference.
Results: We successfully produced a fused cell line that coalesces the gene expression information of hepatocellular
carcinoma cells and stem cells. Experimental results showed that the fused cells expressed cancer and stemness
markers as well as exhibited increased resistance to drug treatment and enhanced tumorigenesis.
Conclusions: Fusion with stem cells transforms liver cancer cells into tumor initiating-like cells. Results indicate that
fusion between cancer cell and stem cell may generate tumor initiating-like cells.
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Background
Cell fusion is a cellular process of combining two or
multiple cells to form a single entity. Today, fusion
with stem cells is used to induce somatic cell nuclei re-
programming and study the cell reprogramming mech-
anism [1]. Cell fusion is also a fast and efficient
approach to induce pluripotent stem cells. The ability
of somatic cells to acquire homologous characteristics
and be converted to pluripotent cells with minimal
modification have been demonstrated through the fu-
sion of stem cells [2–4].
Hepatocellular carcinoma (HCC) is a malignant tumor
with high mortality rate. New therapeutic strategies
against liver cancer are widely discussed in research and
clinical medicine. Stem cell research is a potential ap-
proach to liver cancer treatment [5]. Examples of these
approaches include the injection of stem cell for damage
repair [6], liver regeneration [7], and induced differenti-
ation of hepatocyte cells [8].
This paper presents a study on engineered fusion of
stem cells and cancer cells to explore mechanism of
cancer stem cell that may produce potential influence
to stem cell therapy for liver cancer treatment.
Through laser-induced fusion between a single hepa-
tocellular carcinoma cell (HepG2) and a human embry-
onic stem cell (hESC), we determined that the fused cell
acquired stemness and cancer-like characteristics. The
fused cells exhibited increased tumorigenicity and
resistance to drug treatment. The gene expression analysis
indicated that the fused cells were highly similar to tumor
stem cells (TSCs) or tumor-initiating cells (TICs). TICs
are important in tumorigenesis, aggravation, metastasis,
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Fig. 1 Laser-induced cell fusion of hESC and HepG2. a GFP-labeled hESC (green) and mitochondria-labeled HepG2 (red) forming a cell pair before
laser cutting. b GFP transfer from the green cell to the red cell after laser cutting. c The fused cell attracted to the coverglass surface and exhibited
adherent cell morphology about 25 min after laser cutting. (Scale bar = 20μm)
Wang et al. BMC Cancer  (2016) 16:56 Page 2 of 9and recurrence [9, 10]; liver TICs and their markers were
identified [11–13]. Based on the results of gene expression
analysis and quantity PCR detection, we found that
some liver TIC markers such as CD133, CD44, and
ALDH1 exhibited significantly high expression in the
fused cells. However, this condition was not observed
in HepG2 cells. The in vivo tumorigenicity assay and
drug resistance assay also demonstrated that the
fusion of cancer cells with stem cells resulted in cancer
cells that were highly similar to cancer stem cells.
These results suggested the possibility of incurring
risks when some stem cell therapies are used for
cancer treatment.Table 1 Specific primers used in qPCR
Gene Forward primer (5’-3’)
AFP AGACTGAAAACCCTCTTGAATGC
CD133 ACATGAAAAG ACCTGGGGG
CD44 TCCCAGACGAAGACAGTCCCTGG
ALDH1A1 CTGCTGGCGACAATGGAGT
ABCB1 GGGAGCTTAACACCCGACTTA
EpCAM AATCGTCAATGCCAGTGTACTT
Bcl-2 GACTGAATCGGAGATGGAGACC
β-actin CATCCTCACCCTGAAGTACCCMethods
Cell culture
The hESC line HES2 (NIH code: ES02) from ES Cell
International (passage 60 to 84) was cultured on a com-
mercially available, serum-free, and feeder-independent
system (mTeSR1, Stemcell Technologies) and supple-
mented with BD Matrigel hESC-qualified Matrix (BD
Catalog #354277), as suggested by the manufacturer.
Genetically labeled Oct4-GFP+ hESCs were generated by
transduction (MOI = 5) with lentiviral vectors carrying a
cassette of Oct4 promoter-driven GFP.
HepG2 cells were maintained in DMEM (Gibco, Cata-
log #11965-092), supplemented with 10 % fetal bovineReverse Primer (5’-3’)
GTCCTCACTGAGTTGGCAACA
GATCTGGTGTCCCAGCATG
AT CACTGGGGTGGAATGTGTCTTGGTC
CTGCTGGCGACAATGGAGT
GCCAAAATCACAAGGGTTAGCTT
TCTCATCGCAGTCAGGATCATAA
GCAGTTCAAACTCGTCGCCT
AGCCTGGATAGCAACGTACATG
Fig. 2 Morphology of HepG2, fused cells and hESc. Morphology
of the fused cells differs from that of HepG2 cells and hEScs.
(Scale bar = 20μm)
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penicillin, and 100 U/mL streptomycin (Invitrogen,
Catalog #15240-062) at 37 °C in a humidified atmos-
phere of 5 % CO2.
Cell fusion
Before the fusion experiment, the single cells were ob-
tained with the enzymatic treatment for passaging. After
proper neutralization, the single-cell suspension in the
culture medium was stored temporarily at 4 °C. ToFig. 3 Representative gene marker expression in HepG2 and fused cells. a
CD133 in HepG2, fused cells, and hESCs. Cells in the control group were no
with AFP and CD133 antibody. As hESCs were labeled with GFP, hESCs from
b Gene marker expression analysis shows that both AFP and CD133 were e
affected the gene expression in the fused cellsdistinguish hESCs from HepG2, hESCs were labeled
with Oct-GFP and HepG2 cells were stained with red
mitochondrion selective probe. For mitochondria stain-
ing, the HepG2 single cells were incubated in a 40 nM
MitoTracker probe (Life Technology) for 15 min and
washed three times. The stained cells were re-suspended
in DMEM with 10 % FBS.
The fusion experiment was performed, as described in
the literature [14]. One GFP labeled hESC and one
mitochondria-stained HepG2 cell were trapped and ma-
nipulated using optical tweezers to form a cell pair.
Laser scissors functioned at 10 Hz, and each pulse had a
duration of 1 ns to cut the cell membrane at the point
of contact between the two cells. Successful fusion was
verified by observing the transfer of cytoplasmic GFP
from the hESC to the HepG2 cell (as shown in Fig. 1).
The fused cells attached to the cover glass bottom and
survived.Cell isolation and colony formation
A total of 24 h after fusion, the fused cells were collected
following the trypsin-EDTA treatment and diluted in a
low-density single-cell suspension (6 cells/mL to 10
cells/mL). In each well of a 96-well plate, 100 μL of the
cell suspension was seeded. After 24 h of incubation, the
plate was examined under a microscope, and the wells
containing single cells were selected. Cells were fed with
new DMEM medium every 2 days. After one week of
culturing, colonies formed in the marked wells, and
these colonies, which exhibited different morphologies
than that of HepG2, were gradually replanted to 35 mm
dishes for further characterization.Flow cytometer analysis for the expression of marker protein AFP and
t antibody incubated while cells in the treated group were incubated
both the control and treated groups were green positive population.
xpressed in the fused cells, indicating that both HepG2 and hEScs
Table 2 Significantly enriched GO terms in DEGs
Gene ontology term Cluster frequency Genome frequency of use Corrected p-value
Immune response 10.2 % 4.9 % 2.74e-07
Immune system process 12.4 % 6.8 % 3.77e-06
Response to virus 2.6 % 0.8 % 0.00138
Regulation of apoptosis 7.8 % 4.3 % 0.00508
Regulation of programmed cell death 7.8 % 4.4 % 0.00840
Regulation of cell death 7.8 % 4.4 % 0.00888
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analysis
For each sample, the total RNA was sent to the BGI
Company for RNA-Seq (Quantification) sequencing and
screening of differentially expressed genes (DEGs).
Flow cytometry
We performed FACS tests on HepG2, fused cells and
hESCs, respectively. Cells were detached from culture
dishes and suspended in 100 μl of buffer (Miltenyi
Biotec) and human serum (1:1) for 15 min at 4°C. Cells
were then incubated for 45 min with a primary antibody
for AFP (Santa Cruz Biotechnology, Cat No. sc-8399)
and CD133-PE (Miltenyi Biotec, Cat No. 130-098-829).
Cells were washed with FACS buffer, and incubated for
30 min at 4°C with a secondary antibody (Santa Cruz
Biotechnology, Cat No. sc-2856). Cell labeling was
detected using FACSVerseTM (BD Pharmingen). Flow
cytometry results were analyzed by using BD FACSuite
software.
Quantitative RT-PCR
Total RNA was extracted from the cells with Trizol re-
agent (Invitrogen) using the method provided by the
manufacturer. Reverse transcribed cDNA was producedFig. 4 Drug resistance and related gene expression analysis. a Drug resistanc
(n = 4 for three independent experiments. ***P < 0.01, **P < 0.05. Statisti
b Drug resistance-related gene expressed significantly in fused cells comwith iScriptTM cDNA synthesis kit (Bio-Rad, Cat No170-
8890). Real-time quantitative PCR amplification was per-
formed with SsoAdvanced SYBR Green supermix kit
(Bio-Rad, Cat No. 1725260) in CFX96 Real-time System
(Bio-Rad, USA). The specific primers used in the ana-
lyses are listed in Table 1. The CD133 and CD44 primers
were described in [15] and [16]. Additional primer se-
quences were obtained from the Primer Bank [17].
Drug resistance
The fused cells and HepG2 were first incubated in a 6-well
plate for 15 h. After this step, 0.1, 0.2, and 0.5 μm DOX
were added to the culture medium with three parallel
samples for every group. The cells were incubated for an
additional 48 h. Cell viability was determined through the
trypan blue exclusion test.
In vivo tumorigenicity assay
HepG2 cells and the fused cells (5×104, 1×105, and
1×106 cells in 100 ul DMEM) were subcutaneously
injected into the right scapula of each nude mouse
(BALB/c nu/nu, 4 to 6 weeks old). Four nude mice were
prepared for each group. Tumor growth in the nude
mice was measured every 7 days for 6 weeks. The nude
mice were sacrificed at week 6 or 7. The tumors weree of HepG2 and fused cells examined with different DOX concentrations
cal significance was determined using two-tailed Student’s t-test.
pared with HepG2
Fig. 5 Enhanced tumorigenicity of the fused cells was detected in
nude mice. The in vivo test for tumorigenicity of the fused cells.
a Mice injected with the fused cells (top line) and HepG2 (bottom
line) in the number of 5 × 104 and 1 × 105. Red arrows indicate the
tumors from the fused cell, whereas in the control group, no tumor
was found. b Tumors stripped from the corresponding mice
Table 3 In vivo tumor development experiments of HepG2
cells and fused cells in nude mice
Cell type Cell numbers injected Tumor incidencea Latency (days)b
HepG2 5 × 104 0/4 —
1 × 105 0/4 —
1 × 106 1/2 14
Fused cells 5 × 104 2/4 14
1 × 105 3/4 14
1 × 106 4/4 12
aNumber of tumors detected/number of injections
bApproximate number of days from tumor cell injection to appearance of
a tumor
Wang et al. BMC Cancer  (2016) 16:56 Page 5 of 9fixed with formaldehyde solution and stained with
hematoxylin-eosin (H&E).
Animal care and ethics statement
Male athymic nude mice (BALB/c nu/nu, 4 to 6 weeks
old) were used in this study. These animals were housed
in pathogen-free conditions and provided with food and
water at the facility of LKS Faculty of Medicine, Univer-
sity of Hong Kong (HKU). The Committee on the Use
of Live Animals in Teaching and Research, HKU
approved the protocol.
Statistical analysis
Data on RT-PCR results and drug resistance were
expressed as mean ± SD. Data from in vivo tumor
experiment was expressed as mean ± s.e.m. Statistical
analysis was performed by adopting the two-tailed
Student’s t-test. Differences with p ≤ 0.05 were consid-
ered significant.
Results
Gene expression of the fused cells is different from
HepG2 cells
As shown in Fig. 2, the isolated fused cells did not ex-
hibit a conspicuous spindle shape, which was different
from the morphology of HepG2 cells and hESC. The
marker protein and gene expression of the fused cells
and their parent cells were also detected, and the results
showed that both HepG2 and hESCs affected the fused
cells (see Fig. 3). To identify the functional difference be-
tween the fused cell and the HepG2 cells, we conducted
pairwise comparisons to examine the significantly differ-
ent molecular function, biological process, and cellular
component (Gene Ontology [GO]). As indicated in
Table 2, the immune response, immune system process,
and regulation of apoptosis of the differential expression
genes improved. Similar to CD133, CD44 exhibited a
different expression in the fused cells and HepG2 cells
in the analysis. We conducted qPCR tests for the related
genes. The results showed that several liver tumor-
initiating cell markers, including AFP, CD133, CD44,
and EpCAM [18], were unregulated in the fused cells
compared with those of HepG2 cells (Figs. 3b and 7).
CD133 is an important stemness biomarker in normal
stem cells and TICs, which can help maintain tumori-
genic property and affect the tumor growth of the cells
[19]. CD44 invariant regulates the redox status, which
affects tumor initiation, tumorigenesis, and metastasis
[20]. CD133 and CD44 are rarely expressed in normal
cancer cells. EpCAM is a key protein that activates the
Wnt signaling pathway, which is related to tumorigen-
esis, invasion, and resistance to drug treatments. The
high expression of EpCAM enhances the chemoresis-
tance of cells [21–23].
Wang et al. BMC Cancer  (2016) 16:56 Page 6 of 9Fused cells exhibited increased drug resistance
Drug resistance of the fused cells was also examined.
Fused cells and HepG2 were treated using different con-
centrations of doxorubicin (DOX) for 48 h. Figure 4a il-
lustrates that the survival rate of the fused cell was
significantly higher than that of HepG2 and the survival
rates of the fused cell and HepG2 decreased as DOX
concentration increased. In the present study, survival
rate was defined as the number of viable cells after DOX
treatments divided by the number of viable cells without
DOX treatments. The results demonstrated that the
fused cells exhibited increased drug resistance compared
with their donor HepG2 cells.
The qPCR test results indicated that CD133 (Fig. 3b),
ALDH1A1, ATP-binding cassette sub-family B member
1 (ABCB1), and B-cell lymphoma 2(Bcl-2) (Fig. 4b) wereFig. 6 Histological analysis of the in vivo tumor. The tumors were stained wit
studies, both group were injected with 1 × 106 cells. b The tumors were stain
fused cell and panels 3, 4 were employed to stain tumors induced by the 1 ×
the same injection cell number 1 × 106, the tumor caused the faster growth ohighly expressed in the fused cells. High expression of
CD133 is associated with drug resistance and relapses in
a variety of solid tumors. ALDH is an effective detoxify-
ing enzyme, and a high expression of ALDH can provide
a route for tumors to resist chemotherapy. The expres-
sion of ABCB1 has the capacity of active DNA repair
and resistance to apoptosis [24, 25]. The anti-apoptotic
protein Bcl-2 has been proven to cause resistance to
cancer treatment by forming heterodimers with a
number of pro-apoptotic proteins [26, 27]. Bcl-2 also
contributes to the resistance to a wide spectrum of
chemotherapeutic agents [28, 29]. The expression of
CD133, ABCB1, Bcl-2, and ALDH1A1 in the fused cells
explains the increased drug resistance of the fused cell
[30], suggesting that the cancer cell would acquire drug
resistance through cell fusion with the stem cell.h hematoxylin-eosin (H&E). a Tumors (arrows) used for the histological
ed with H&E. Panels 1, 2 were used to stain tumors induced by 1 × 106
106 HepG2 cells. c Tumor size detected six weeks after cell injection. In
f fused cells than the tumor caused by HepG2
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To analyze tumor-initiating capability, nude mice were
transplanted with various amounts of the fused cells.
The same amounts of HepG2 cells were used as the con-
trol. The tumor volume was measured weekly. The fused
cells could result in progressively growing tumors in the
nude mice with fewer cells compared with HepG2 cells.
The injection of fused cells at 5 × 104 facilitated the pro-
gressive growth of tumors in the nude mice, whereas the
injection of HepG2 cells at 5 × 104 did not induce this
effect (Fig. 5). Tumor incidence increased when the in-
jection dose of the fused cells was raised to 1 × 105.
However, tumors were still not formed in the mice
injected with the same amount of HepG2 cells. When
the injected cells were increased to 1 × 106, both the
fused and HepG2 cells promoted tumor growth in the
nude mice. The fused cells induced 100 % tumor inci-
dence, whereas the HepG2 cells induced only 50 %
tumor incidence. The fused cell possessed higher
tumorigenicity and faster tumor growth than the HepG2
cells (Table 3 and Fig. 6c).
As shown in Fig. 5a and b, the xenograft tumors ex-
hibited similar histological features in the mice injected
with the fused cells or HepG2 cells, which indicated that
the tumor tissue was not a teratoma induced by hESCs.
The result of in vivo tumorigenicity assay showed that
the fused cells exhibited increased tumorigenicity
in vivo. The highly expressed CD133 (Fig. 3), CD44, and
EpCAM may illustrate the mechanism of enhanced
tumorigenicity (Fig. 7a). The expression of two tumor
proliferation factors, proliferating cell nuclear antigen
(PCNA) and ki67 were also detected. The qPCR results
indicated that both PCNA and Ki67 were expressedFig. 7 Tumorigenicity-related gene expression analysis. The tumorigenicity-
surface molecule that affects tumorigenesis. EpCAM is the activator of WNT p
proliferation cell nuclear antigens. All of these genes are highly expressed in trelatively high in the fused cell (Fig. 7b). The high ex-
pression of PCNA indicates the high risk of carcinogen-
esis [31]. Ki67 is a nuclear antigen expressed in a variety
of solid malignant tumors, and its expression level is sig-
nificantly higher than that of normal tissue. Ki67 is
closely related to the development, metastasis, and prog-
nosis of malignant tumors [32, 33].
Discussions
Using engineered laser-induced single-cell fusion tech-
nology, we have successfully produced a fused cell line,
which coalesces the gene expression information of he-
patocellular carcinoma cells and stem cells. Experimental
results verified that the fused cells are highly tumori-
genic and chemoresistant compared with the donor he-
patocellular carcinoma cells. The fusion of stem cells
and cancer cells enables the hybrids to exhibit stemness
and cancer characteristics. Traditionally, during stem
cell induced reprograming of somatic cell via fusion, the
somatic pluripotency gene epigenetic modifications has
been recognized to be a crucial factor, which has been
explained as one of the parental cells dominating pheno-
type over the other [34]. The epigenetic modifications
include chromatin remodeling, histone modification and
DNA demethylation [35, 36]. However, the mechanism
of fusion between cancer cells and stem cells are rarely
elaborated.
Our study on artificially engineered fusion of stem
cells and liver cancer cells demonstrated a possible
mechanism of the tumor-initiating cell generation in the
human body. The fusion of stem cells can occur spon-
taneously in vivo after stem cell injection or transplant
[37]; thus, our research may explain the risk induced byrelated gene expressions were detected by qPCR. a CD44 is a cell
athway, which is important in cancer cells. b PCNA and Ki67 are tumor
he fused cells (p < 0.05)
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stem cell therapies may generate cancer stem-like cells
and exacerbate cancer instead of curing the disease. On
the other hand, the artificial generation of tumor
initiating-like cells can be used to produce malignant
cells for cancer stem cell drug screening and studies on
its mechanism.
Conclusions
We artificially fused a HepG2-hESC cell pair and isolated
a fused cell line. The genetic analysis result demonstrated
that the fusion of cancer cells with stem cells resulted in
cancer cells that were more tumorigenic and exhibited
higher chemoresistance. The result also indicated that the
fused cells were highly similar to tumor-initiating cells in
biological processes or cellular compartments. The related
gene expressions, such as CD133, CD44, and EpCAM, in
the fused cells also supported this conclusion. In the fu-
ture work, we will continue to explore the stem cell mech-
anism (e.g., functional protein assay and GO comparison
to original TICs), as well as conduct more sufficient
in vivo experimental study.
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